The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...

SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a ...

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...

Tanvi Lodhia’s path to pharma marketing may sound familiar to her peers in the industry: Like many of them, for example, she ...

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficac ...

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological ...

Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...

Argenx (ARGX) announced that Health Canada has issued a notice of compliance authorizing Vyvgart as a monotherapy for the treatment of adult ...